Clinical Trial Detail

NCT ID NCT03082534
Title Pembrolizumab Combined With Cetuximab for Treatment of Recurrent/Metastatic Head & Neck Squamous Cell Carcinoma
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Assuntina G. Sacco

head and neck squamous cell carcinoma


Cetuximab + Pembrolizumab

Age Groups: adult senior

No variant requirements are available.